Fiscal Estimate - 2009 Session

Original Updated	Corrected Supplemental								
LRB Number 09-2221/1	Introduction Number AB-0254								
Description A sales tax and use tax exemption for nonprescription drugs									
Fiscal Effect									
Appropriations Rev	ease Existing enues rease Existing enues to absorb within agency's budget ENUMBER OF THE PROPERTY OF THE PROPE								
☐ No Local Government Costs ☐ Indeterminate 1. ☐ Increase Costs ☐ Permissive ☐ Mandatory ☐ Perm	5.Types of Local Government Units Affected Towns Village Counties Counties Others Districts 5.Types of Local Government Units Affected Towns Village Stadium Districts Districts								
Fund Sources Affected Affected Ch. 20 Appropriations GPR FED PRO PRS SEG SEGS									
Agency/Prepared By	Authorized Signature Date								
DOR/ Jacek Cianciara (608) 266-8133	Paul Ziegler (608) 266-5773 5/27/200								

Fiscal Estimate Narratives DOR 5/27/2009

LRB Number 09-2221/1	Introduction Number	AB-0254	Estimate Type	Original				
Description								
A sales tax and use tax exemption for nonprescription drugs								

Assumptions Used in Arriving at Fiscal Estimate

The bill exempts from sales and use tax nonprescription drugs that are for human consumption only, prepackaged for use by consumers, and labeled in accordance with the requirements of state and federal law. The exemption would take effect on July 1, 2011.

The bill would not have any fiscal impact on FY10 and FY11.

According to the most recent available data, nationwide retail sales of nonprescription drugs were about \$13.2 billion in 2005. Based on annual increases in personal consumption expenditures for medical care, including non-prescription drugs, it is estimated that nationwide retail sales of nonprescription drugs will increase to \$16.3 billion by FY12. Nonprescription drugs in this estimate include products for allergy relief, cold medications, cough drops, decongestants, antacids, pain relief medications, sleep aids, and other products. Vitamins and other nutritional products are excluded from this estimate because Wisconsin's definition of "drug" (effective October 1, 2009) excludes dietary supplements.

Assuming the percentage share of nonprescription drugs purchased by Wisconsin consumers is the same as Wisconsin's share of disposable personal income, sales of nonprescription drugs in Wisconsin are estimated to be \$284.7 million in FY12.

Based on the July 1, 2011 effective date, and assuming a 95% compliance rate, sales and use taxes would decrease in FY12 by a minimum of \$13.4 million under the bill.

Beyond the products considered above, however, the bill would also exempt grooming and hygiene products that are treated and regulated as drugs. These items include shampoos, toothpastes, mouthwashes, antiperspirants and other products that are required to carry "Drug Facts" or "active ingredients" labeling. Information on the portion of these products that would fall under state and federal definitions of "drug" is not available. Consequently, it is not possible to provide an estimate of the revenue loss that would be incurred by grooming and hygiene products that would become exempt under the bill. This revenue loss could, however, be substantial.

County and stadium sales taxes were about 7.85% of state sales taxes in FY08. Assuming this percentage remains unchanged, county and stadium sales taxes would decrease by a minimum of \$1.1 million in FY12.

The Department of Revenue's costs to administer the bill are minimal and would be absorbed within existing budget authority.

Long-Range Fiscal Implications

Fiscal Estimate Worksheet - 2009 Session

Detailed Estimate of Annual Fiscal Effect

\boxtimes	Original		Updated		Corrected		Supplemental		
LRB	Number	09-2221	/1	Intro	duction Nu	umber	AB-0254		
Description A sales tax and use tax exemption for nonprescription drugs									
I. One-time Costs or Revenue Impacts for State and/or Local Government (do not include in annualized fiscal effect):									
II. Ann	ualized Cos	ts:			Annualized Fiscal Impact on funds from:				
					Increased Co	sts	Decreased Costs		
	te Costs by								
	e Operations		d Fringes			\$	\$		
<u> </u>	Position Ch								
	State Operations - Other Costs			_					
	al Assistance								
	to Individual								
	OTAL State (Costs by Ca	tegory			\$	\$		
	te Costs by	Source of Fu	unds	· •					
GPF	}								
FED									
<u> </u>)/PRS								
	SSEG-S								
			this only wh ecrease in lic			e or decre	ase state		
					Increased F	Rev	Decreased Rev		
GPF	Taxes					\$	\$-13,400,000		
GPF	REarned								
FED									
<u></u>)/PRS								
	SEG/SEG-S				0	0			
TOTAL State Revenues					\$0	\$-13,400,000			
NET ANNUALIZED FISCAL IMPACT									
					Sta	ate	Local		
NET CHANGE IN COSTS					\$	\$			
NET CHANGE IN REVENUE			\$-13,400,0	000	-\$1,100,000				
Agency/Prepared By Au			Authorized	Signature		Date			
DOR/ Jacek Cianciara (608) 266-8133 Pa				Paul Ziegler	Ziegler (608) 266-5773 5/27/2				